Research Projects & Grants

For Profit Organization

  • A multicenter, open-label, long term safety study of H 199/18 40 mg in subjects with healed erosive esophagitis, Role: Investigator, ASTRA (USA), (10/1998 - 10/1999) Status: Completed
  • A twelve-week randomized, double blind, placebo-controlled, multi-center study of alosetron in female subjects with irritable bowel syndrome - phase III, Role: Investigator, Glaxo Wellcome Foundation, (08/1998 - 08/1999) Status: Completed
  • A multicenter, randomized, double blind, eight week comparative efficacy and safety study of H199/18 20 mg and omeprazole 20 mg in study subjects with erosive esophagitis, Role: Investigator, ASTRA (USA), (10/1997 - 10/1998) Status: Completed
  • Controlled trial of reversal of Barrett's Esophagus with acid suppression and multi-polar electrocoagulation, Role: Investigator, TAP Pharmaceuticals, Inc,, (07/1997 - 07/1998) Status: Completed

Internal

  • Radiofrequency ablation (RFA) using HALO device vs Argon plasma coagulation (APC) for GAVE (gastric antral vascular ectasia) lesions, Role: PI, LLU Dept. of Gastroenterology, (07/2013 - 06/2014) Status: Completed
  • Factors influencing the natural history of bleeding peptic ulcers, Role: Investigator, LLU Dept. of Medicine, (07/1998 - 07/1999) Status: Completed
  • Morphine and gastroduodenal motility, Role: PI, LLU GI Research Fund, (02/1997 - 02/1998) Status: Completed